However, a study in head and neck squamous cell carcinoma described a characteristic promoter methylation pattern of ZNF10, TMPRSS12, ERGIC2, and RNF215 genes, which was proposed as a biomarker of response to radiotherapy treatment (33). This evidence concerns the gene ERGIC2 and head and neck squamous cell carcinoma.